Author

M. Diolaiti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 2 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:deep learning· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:protein structure· 2 Approach:statistical model· 2 Assay:CRISPR screen· 1

Frequent Co-Authors

A. Ashworth· 4 shared G. J. Correy· 2 shared J. S. Fraser· 2 shared A. Marson· 1 shared A. R. Renslo· 1 shared B. K. Shoichet· 1 shared C. Bui· 1 shared C.-L. Tsou· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiophysics

A. Ashworth

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

De novo design of drug-binding proteins with predictable binding energy and specificity

L. Lu, X. Gou, S. Tan, S. Mann, H. Yang, X. Zhong, D. Gazgalis, J. Valdiviezo, H. Jo, Y. Wu, M. Diolaiti, A. Ashworth, N. Polizzi, W. DeGrado

This paper designs drug-binding proteins with low nanomolar affinity and predictable specificity using computational methods, validated by experimental measurements and structural analysis.

bioRxiv · Dec 23, 2023 · PreprintBiophysics

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo

T. Y. Taha, R. K. Suryawanshi, I. P. Chen, G. J. Correy, P. C. O'Leary, M. P. Jogalekar, M. McCavitt-Malvido, M. Diolaiti, G. R. Kimmerly, C.-L. Tsou, L. Martinez-Sobrido, N. J. Krogan, A. Ashworth, J. S. Fraser, M. Ott

This study shows that mutating the SARS-CoV-2 NSP3 Mac1 domain reduces viral replication and pathogenesis in vivo.

bioRxiv · Apr 18, 2023 · PreprintMicrobiology

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2

S. Gahbauer, G. J. Correy, M. Schuller, M. P. Ferla, Y. U. Doruk, M. Rachman, T. Wu, M. Diolaiti, S. Wang, J. Neitz, D. Fearon, D. S. Radchenko, Y. Moroz, J. J. Irwin, A. R. Renslo, , J. S. Fraser

The paper computationally designs and experimentally validates potent inhibitors of the SARS-CoV-2 Nsp3 Macrodomain, identifying 160 ligands and 152 crystal structures with submicromolar affinity.

bioRxiv · Jun 27, 2022Biophysics

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

E. Shifrut, J. Carnevale, V. Tobin, T. L. Roth, J. M. Woo, C. Bui, P. J. Li, M. Diolaiti, A. Ashworth, A. Marson

This study uses CRISPR screens in primary human T cells to identify regulators of immune function and cancer cell killing.

bioRxiv · Aug 3, 2018Immunology